Total Funding
78
63
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
41125
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
- John Cox: President and Chief Executive Officer
- Molly White: Vice President, Medical Communications & Advocacy
About the Company
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives.
